3篇
您的检索式：作者名="Merle G PAULE"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein aneurysm: A rare but important vascular condition显示文摘 | Patricia A Brock Paul H Jordan Merle H Barth Alan G Rose | 1997 | Surgery1997，，1： | 1 |
| 2 | A common genetic mechanism underlying susceptibility to posttraumatic stress disorder显示文摘We hypothesize that susceptibility to post-traumatic stress disorder(PTSD) may be determined in part by aberrant microtubule-associated protein tau expression in neurons of critical brain structures. The following lines of evidence support this hypothesis. First, epidemiologic data suggest the involvement of genetic factors in the susceptibility to PTSD. Second, the common features of both abnormal tau expression and PTSD include amygdalar and hippocampal atrophy, upregulation of norepinephrine biosynthetic capacity inthe surviving locus coeruleus neurons and dysfunction of N-methyl-D-aspartate-receptors. Finally, our experiments using r Tg4510 mice, a model that over-expresses human mutant tau and develops age-dependent tauopathy, demonstrate that these animals display circling behavior thought to be related to states of anxiety. To detect the potential molecular mechanisms underlying PTSD episodes, laser-assisted/capture microdissection can be used with microarray analysis as an alternative approach to identify changes in gene expression in excitatory and/or inhibitory neurons in critical brain structures(i.e., hippocampus and amygdala) in response to the onset of PTSD. | Zhen He Li Cui Bei He Sherry A Ferguson Merle G Paule | 2013 | World Journal of Neurology2013，3，3： | 0 |
| 3 | Pharmacological characterizationof synthetic cannabinoid MAM-2201:radioligand binding and abuse-related effects显示文摘OBJECTIVE Over 30% of all new psychoactive substances identified by the UN Office on Drugs and Crime in 2016 were synthetic cannabinoids.The recent emergence of MAM-2201 on the illicit market is troubling because this drug has no precedent in either the scientific or patent literature,and appears to be a novel compound developed specifically as a 'graymarket' drug of abuse bystructurally combining the known synthetic cannabinoids JWH-122 and AM-2201.There is currently no published information regarding the pharmacology of MAM-2201.METHODS The present studies characterized cannabinoid-like effects of MAM-2201 in vitro(interactions with cannabinoid type 1 receptors[CB1 Rs]) and in vivo(in mice and rats).RESULTS In a radioligand binding assay using [3 H]CP55,940 in HEK cell membranes transfected with the CB1 R,MAM-2201(K i=5.4 nmol·L^(-1)),had higher binding affinity than WIN 55,212-2(K i=80 nmol·L^(-1)),and D9-THC(K i=8.3 nmol·L^(-1)).The E max values for MAM-2201 and WIN 55,212-2 in an assay of agonist inhibition of forskolin-stimulated c AMP were 85%(EC50=0.45 nmol·L^(-1)) and 95%,respectively,as compared with the D9-THC E max of 74%.In mice,MAM-2201(0.003-1.0 mg·kg^(-1),IP) produced dose-dependent cannabimimetic effects which were both more potent and more effective than those of D9-THC.MAM-2201 and D9-THC dose-dependently produced hypothermia:ED50=0.287 and 25.4 mg·kg^(-1),analgesia:ED50=0.125 and 29.4 mg·kg^(-1),and catalepsy:ED50=0.301 and18.9 mg·kg^(-1) in adult male CD1 mice.Importantly,MAM-2201 also elicited convulsant effects at a dose of 1.0 mg·kg^(-1) in 8/8 murine subjects.In rats,MAM-2201 produced dose-dependent D9-THC-like interoceptive effects in subjects trained to discriminate 3.0 mg·kg^(-1)(IP) D9-THC from saline.CONCLUSION MAM-2201 binds CB1 Rs with high affinity and agonist efficacy,and functions as a potent cannabinoid agonist in vivo across several complementary measures of cannabinoid activity in two rodent species. | William E FANTEGROSSI Aaron JANOWSKY Amy J ESHLEMAN Lauren N RUSSELL Saki FUKUDA Jyoti GOGOI Cassandra PRIOLEAU Ambuja S BALE Srihari R TELLA Merle G PAULE Takato HIRANITA | 2017 | 中国药理学与毒理学杂志2017，31，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员